跳至主要内容
临床试验/EUCTR2011-003081-32-NL
EUCTR2011-003081-32-NL进行中(未招募)不适用

DABIRENAL STUDY A study to investigate the pharmacokinetics and effects of Dabigatran in patients with stable severe chronic kidney disease - lumc-30706-IV

eiden University Medical Center0 个研究点开始时间: 2012年2月24日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Age: 18 years and older
  • Able and willing to give informed consent
  • Impaired renal function defined as a stable MDRD and/or creatinine clearance
  • estimated using urinary excretion between 15-30 ml/min over the last 3 months
  • before study participation
  • The single use of either aspirin or Vitamin K-antagonists
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 16
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • -Instable renal function (i.e. an increase in serum creatinine > 20% in the last three months)
  • -Patients treated with two or more platelet aggregation inhibitors
  • -Use of or indication for therapeutic (low molecular weight) heparin
  • -Patients with mechanic heart valves
  • -Any known bleeding disorder or tendency
  • - Uncontrolled hypertension (systolic >180mmHg or diastolic >100mmHg)
  • - Diabetes mellitus with active retinopathy
  • - Pre-menopausal women not willing to use appropriate contraception (e.g. oral anti conceptive
  • drugs or intrauterine devices)
  • - Recent cerebral bleeding or cranio-cerebral trauma (within the last six months)
  • - Moderate to severe liver impairment (ALT >2 ULN)
  • - Gastrointestinal surgery within the last three months (except for appendectomy,
  • cholecystectomy or herniotomy)
  • - Use of P-glycoprotein inhibitors
  • - Relevant acute infections (e.g. acute pneumonia)
  • - History of allergy or hypersensitivity (including drug allergies) deemed relevant by the
  • investigator
  • - Planned diagnostic or therapeutic procedures with potential for uncontrollable bleeding within
  • 30 days before, during or after the trial
  • - Indication of past of present use of drugs or abuse
  • - Past history of alcoholism with clinical sequelae or present use of alcohol >3U daily (male)
  • or 2U daily (female)
  • - Participation in another drug trial

研究者

发起方
eiden University Medical Center

相似试验